35 articles, transcripts, and reports
Gilead Sciences Inc. (GILD) Q1 2020 earnings call dated April 30, 2020 Corporate Participants: Douglas Maffei — Investor Relations Daniel O’Day — Chairman and Chief Executive Officer Andrew Dickinson — Chief…
Biopharmaceutical company Gilead Sciences Inc (NASDAQ: GILD) Thursday said its first-quarter earnings increased, aided by higher revenues. The results also exceeded the market’s prediction. The…
Gilead Sciences Inc (NASDAQ: GILD) Q4 2019 Earnings Conference Call February 04, 2020 Corporate Participants: Douglas Maffei — Investor Relations Daniel O’Day — Chairman and Chief Executive Officer Andrew Dickinson — Chief…
Biopharmaceutical company Gilead Sciences, Inc. (NASDAQ: GILD) reported a decline in fourth-quarter earnings, despite a modest increase in revenues. Earnings fell short of expectations, while…
— Gilead Sciences (NYSE: GILD) reported third-quarter 2019 earnings of $1.75 per share, vs. $1.74 per share expected. — Total revenue remained flat at $5.60…
